Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
3.190
+0.060 (1.92%)
At close: Nov 7, 2025, 4:00 PM EST
3.400
+0.210 (6.58%)
After-hours: Nov 7, 2025, 7:47 PM EST
Cellectis Revenue
Cellectis had revenue of $37.16M in the quarter ending September 30, 2025, with 105.88% growth. This brings the company's revenue in the last twelve months to $82.55M, up 129.04% year-over-year. In the year 2024, Cellectis had annual revenue of $49.22M with 435.37% growth.
Revenue (ttm)
$82.55M
Revenue Growth
+129.04%
P/S Ratio
2.90
Revenue / Employee
$371,851
Employees
222
Market Cap
239.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CLLS News
- 1 day ago - Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 days ago - Cellectis to Present a Development Update for eti-cel at ASH 2025 - GlobeNewsWire
- 8 days ago - Cellectis to Report Third Quarter Financial Results on November 7, 2025 - GlobeNewsWire
- 23 days ago - Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL - GlobeNewsWire
- 23 days ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 23 days ago - Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers - GlobeNewsWire
- 4 weeks ago - Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress - GlobeNewsWire
- 3 months ago - Cellectis S.A. (CLLS) Q2 2025 Earnings Call Transcript - Seeking Alpha